氯吡格雷抵抗与基因多态性  

Clopidogrel resistance and genetic polymorphism

作　　者：孙文珊[1] 李永坤[1] 徐格林[1] 

机构地区：[1]南京大学医学院临床学院,南京军区南京总医院神经内科,210002

出　　处：《国际脑血管病杂志》2011年第11期841-844,共4页International Journal of Cerebrovascular Diseases

基　　金：基金项目：国家自然科学基金（30870847）

摘　　要：氯吡格雷是目前广泛应用于临床的一种抗血小板药，已作为心肌梗死、缺血性卒中和周围血管病的二级预防用药。然而，氯吡格雷的抗血小板聚集效果存在显著的个体差异，很大一部分患者存在抵抗现象。氯吡格雷抵抗的机制尚不完全清楚，基因多态性是氯吡格雷抵抗的一个重要原因，包括ABCBl、CYP2C19、CYP3A4、CYP3A5、P2Y12和ITGB3等。Clopidogrel is an antiplatelet drug widely used in clinical practice now. It has been used as the secondary prevention medication for myocardial infarction, ischemic stroke, and peripheral vascular disease. However, the anti-platelet aggregation effect of clopidogrel has significant individual differences. A large part of patients have clopidogel resistance phenomenon. The mechanism of clopidogel resistance is not fully understood. The genetic polymorphism is an important cause of clopidogrel resistance, including ABCB1, CYP2C19, CYP3A4, CYP3A5, P2Y12, and 1TGB3.

关 键 词：氯吡格雷 抗药性 血小板聚集抑制药 多态现象 遗传学 细胞色素P450酶系统 受体 嘌呤能P2Y12 卒中 心肌梗死 

分 类 号：R973.2[医药卫生—药品]